Condition: Nasopharyngeal Carcinoma · Chemotherapy · Radiotherapy · Sponsor: Sun Yat-sen University
Through multicenter, open-label, randomised clinical trials, we intend to demonstrate that concurrent and adjuvant PD-1 treatment added to concurrent chemo-radiotherapy could further decrease the rate of disease progression and improve the survival outcome of patients with unresectable locally recurrent nasopharyngeal carcinoma compared with those treated with concurrent chemo-radiotherapy alone.
This description comes directly from the study's public registry record.
Ming-Yuan Chen, MD, PhD · : 86-20-87343624 · chmingy@mail.sysu.edu.cn
Rui You, MD, PhD · 86-13580439820 · yourui@sysucc.org.cn
Always discuss trial participation with your own doctor first.
| Sun Yat-sen University Cancer Center | Guangzhou, Guangdong, China | Recruiting |
| Cancer Center of Guangzhou Medical University | Guangzhou, Guangdong, China | Not Yet Recruiting |
| Yuebei People's Hospital | Shaoguan, Guangdong, China | Not Yet Recruiting |
| Zhongshan People's Hospital | Zhongshan, Guangdong, China | Not Yet Recruiting |
| The Fifth Affiliated Hospital of Sun Yat-sen University | Zhuhai, Guangdong, China | Not Yet Recruiting |
| Wuzhou Red Cross Hospital | Wuzhou, Guangxi, China | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT04453813